Zheng Wei, Connect Biopharma CEO

Con­nect Bio­phar­ma cel­e­brates a mid-stage win for its Dupix­ent ri­val, but shares tank af­ter in­vestors clam­or for da­ta

A suite of drug­mak­ers is look­ing to top­ple Dupix­ent in the eczema mar­ket — and on Thurs­day, Chi­na-based Con­nect Bio­phar­ma un­corked some mid-stage re­sults it says will pave the way to a piv­otal tri­al. But in­vestors want hard num­bers, and with­out any to share, the com­pa­ny’s stock $CNTB plunged more than 50% on Fri­day.

Con­nect’s mon­o­clon­al an­ti­body CBP-201 met the pri­ma­ry end­point in a Phase II tri­al, show­ing sig­nif­i­cant im­prove­ments in Eczema Area and Sever­i­ty In­dex (EASI) scores in all three dose groups, ac­cord­ing to the biotech. The treat­ment arms — 300 mg every two weeks, 150 mg every two weeks, or 300 mg every four weeks — were all sta­tis­ti­cal­ly su­pe­ri­or to place­bo at Week 16, and all showed sig­nif­i­cant im­prove­ments in the pro­por­tion of pa­tients achiev­ing at least a 50% or 75% re­duc­tion in EASI score (EASI-50 or EASI-75, re­spec­tive­ly).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.